Current Roles

Employees:
132
Revenue:
$26.5M
About
Tonix is developing innovative pharmaceutical products to address major public health challenges. In addition to Tonmya for PTSD, Tonix is developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (Investigational New Drug) application stage, designed as a daytime treatment for PTSD and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage, to be developed as a potential smallpox-preventing vaccine. Further information about Tonix can be found at www.tonixpharma.com.
Tonix Pharmaceuticals Holding Corp. (TNXP) Address
26 Main Street
New York, NY
United States
Tonix Pharmaceuticals Holding Corp. (TNXP) Email
Tonix Pharmaceuticals Holding Corp. (TNXP) Phone Numbers
862-799-8599

Past Companies

Tonix PharmaceuticalsCEO
Columbia UniversityAssociate Professor

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.